Autologous CD133+ cells augment the effect of portal embolization.
Minerva Chir
; 68(2): 163-8, 2013 Apr.
Article
em En
| MEDLINE
| ID: mdl-23612229
ABSTRACT
AIM:
The standard to treat liver tumors is a resection. When the future liver remnant (FLRV) is below 30% (healthy livers) or 40% (cirrhotic livers or previous chemotherapy), surgery carries the risk of severe complications. Portal vein embolization (PVE) gained a worldwide diffusion as a tool to augment the FLRV. Cell therapies are recent players at the frontiers of medicine. This study presents a clinical experience to evaluate the synergistic effect of combined PVE and autologous CD133+ cells coadministration.METHODS:
Sixteen patients have been enrolled in the study up today. Inclusion criteria were primary or metastatic liver malignancy with a FLRV<30% or 40%. A baseline volumetric CT-scan was obtained. CD34+ were mobilized to the blood stream by G-CSF administration and collected by immunomagnetic separation. Simultaneously with PVE, cells were administered to the non occluded liver segments. Follow-up CT scans were taken at 30th post treatment day.RESULTS:
The patients (N.=6) showed an increased volume gain (Mann-Whitney test P<0.001, two sided) compared to a set of cases whose treatment was PVE only (N.=10).DISCUSSION:
The use of autologous stem cells as an augmenter of liver regeneration has a clinical potential to improve the resectability of liver tumors.
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Peptídeos
/
Veia Porta
/
Glicoproteínas
/
Antígenos CD
/
Transplante de Células-Tronco de Sangue Periférico
/
Embolização Terapêutica
/
Neoplasias Hepáticas
/
Regeneração Hepática
Idioma:
En
Ano de publicação:
2013
Tipo de documento:
Article